Rhythm Pharmaceuticals (BMV:RYTM *) - Stock Price, News & Analysis

RYTM * Stock Overview

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.

About the company

RYTM * fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 78.4% below our estimate of its fair value

Earnings are forecast to grow 60.89% per year

Risk Analysis

Shares are highly illiquid

Shareholders have been diluted in the past year

Rhythm Pharmaceuticals, Inc. Competitors

Telix Pharmaceuticals

ASX:TLX

AU$4.1b

Sinocelltech Group

SHSE:688520

CN¥16.6b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$1.6b

Beam Therapeutics

NasdaqGS:BEAM

US$2.0b

Price History & Performance

Summary of all time highs, changes and price drops for Rhythm Pharmaceuticals
Historical stock prices
Current Share Price	US$646.91
52 Week High	US$733.48
52 Week Low	US$308.00
Beta	1.93
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	75.23%
3 Year Change	45.84%
5 Year Change	n/a
Change since IPO	51.22%

Recent updates

Shareholder Returns

	RYTM *	MX Biotechs	MX Market
7D	0%	0%	0%
1Y	75.2%	0%	0%

Return vs Industry: RYTM * exceeded the MX Biotechs industry which returned -8% over the past year.

Return vs Market: RYTM * exceeded the MX Market which returned 0.6% over the past year.

Price Volatility

Is RYTM *'s price volatile compared to industry and market?
RYTM * volatility
RYTM * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stable Share Price: RYTM * has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine RYTM *'s volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2008	226	David Meeker	rhythmtx.com

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.

Rhythm Pharmaceuticals, Inc. Fundamentals Summary

How do Rhythm Pharmaceuticals's earnings and revenue compare to its market cap?
RYTM * fundamental statistics
Market cap	Mex$39.77b
Earnings (TTM)	-Mex$3.13b
Revenue (TTM)	Mex$1.31b

30.3x

P/S Ratio

-12.7x

P/E Ratio

Is RYTM * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RYTM * income statement (TTM)
Revenue	US$77.43m
Cost of Revenue	US$9.30m
Gross Profit	US$68.13m
Other Expenses	US$252.80m
Earnings	-US$184.68m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-3.03
Gross Margin	87.99%
Net Profit Margin	-238.52%
Debt/Equity Ratio	62.5%

How did RYTM * perform over the long term?

See historical performance and comparison

RYTM * Stock Overview

Rewards

Risk Analysis

Rhythm Pharmaceuticals, Inc. Competitors

ASX:TLX

AU$4.1b

SHSE:688520

CN¥16.6b

NasdaqGS:AGIO

US$1.6b

NasdaqGS:BEAM

US$2.0b

Price History & Performance

Recent News & Updates

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, Discovery Real Estate Management

Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist

Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc. Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for Imcivree® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Forecast to breakeven in 2026

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

Rhythm Pharmaceuticals, Inc. Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Rhythm Pharmaceuticals, Inc. Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

Rhythm Pharmaceuticals, Inc. Announces Approval of IMCIVREE®? Setmelanotide Solution for Weight Management in Adult and Pediatric Patients

First quarter 2023 earnings released: US$0.92 loss per share (vs US$1.05 loss in 1Q 2022)

Full year 2022 earnings released: US$3.48 loss per share (vs US$1.40 loss in FY 2021)

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces ?Imcivree (Setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-Term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity At Obesityweek® and Plans to Initiate Phase 3 Trial in Early 2023

Rhythm Pharmaceuticals, Inc. Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Rhythm Pharmaceuticals, Inc. Announces European Commission Expands the Marketing Authorization for Imcivree(R) (Setmelanotide)

Second quarter 2022 earnings released: US$0.89 loss per share (vs US$0.70 loss in 2Q 2021)

Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Announces Early Access Authorization for Setmelanotide for Use in Patients with Bardet-Biedl Syndrome in France

NICE Recommends Rhythm’s IMCIVREE® (setmelanotide) for Treating Obesity and Controlling Hunger Caused by POMC or LEPR Deficiency

Rhythm Pharmaceuticals Announces Positive Interim Results from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. Announces That European Commission Authorized Variation for Imcivree (Setmelanotide) to Allow for Dosing in Patients with POMC or LEPR Deficiency with Renal Impairment

Rhythm Pharmaceuticals, Inc. Announces FDA Approval of IMCIVREE for Use in Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals Presents Initial Data from Long-Term Extension Trial Evaluating Setmelanotide in Rare Genetic Diseases of Obesity at ENDO 2022

Rhythm Pharmaceuticals, Inc. Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome At the Pediatric Endocrine Society 2022 Virtual Annual Meeting

Rhythm Pharmaceuticals Optimizes Design of EMANATE and DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity

Forecast to breakeven in 2024

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

Rhythm Pharmaceuticals, Inc. Announces Executive Promotions

Rhythm Pharmaceuticals, Inc. Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

Rhythm Pharmaceuticals, Inc. Announces Dosing Initiated in Phase 3 Trial of Weekly Setmelanotide in Patients with Genetic Obesity Disorder

High number of new directors

Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain

Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for IMCIVREE® (Setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl and Alström Syndromes

Rhythm Pharmaceuticals, Inc Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome

Rhythm Pharmaceuticals, Inc. Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity

Rhythm Pharmaceuticals, Inc. Announces European Commission Authorization of IMCIVREE

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index